Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor Enasidenib

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Med
Main Authors: Quek, Lynn, David, Muriel D., Kennedy, Alison, Metzner, Marlen, Amatangelo, Michael, Shih, Alan, Stoilova, Bilyana, Quivoron, Cyril, Heiblig, Maël, Willekens, Christophe, Saada, Véronique, Alsafadi, Samar, Vijayabaskar, MS, Peniket, Andy, Bernard, Oliver A, Agresta, Sam, Yen, Katharine, MacBeth, Kyle, Stein, Eytan, Vassiliou, George S., Levine, Ross, De Botton, Stephane, Thakurta, Anjan, Penard-Lacronique, Virginie, Vyas, Paresh
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6925974/
https://ncbi.nlm.nih.gov/pubmed/30013198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0115-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados